Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis

NCT01373710 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT01373710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01373710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis
Lead sponsor
Institut Curie
Phase
Phase 1/2
Overall status
Completed
Start date
May 19, 2011
Completion date
April 9, 2018
Enrollment
34 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinomatous meningitis, metastatic breast cancer